Ensemble Therapeutics Corporation

Ensemble Discovery Names Richard F. Begley as CEO; Begley Leverages Knowledge of Chemistry, Biology and Engineering

Ensemble Discovery Names Richard F. Begley as CEO; Begley Leverages Knowledge of Chemistry, Biology and Engineering

April 4, 2005

CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 4, 2005--Ensemble Discovery Corporation, an early stage company developing a revolutionary approach to create new products in life Sciences, materials, and chemicals through its proprietary DNA Programmed Chemistry(TM) platform, has named Richard F. Begley, Ph.D., as president and chief executive officer.

Morphotek, Inc.

Morphotek Announces Multi-Year, Research Collaboration Agreement with Amgen to Optimize Expression of Antibodies

Morphotek Announces Multi-Year, Research Collaboration Agreement with Amgen to Optimize Expression of Antibodies

April 18, 2005

Exton, PA -- April 18, 2005 -- Morphotek Inc. today announced that it has entered into a multi-year Research Collaboration Agreement with Amgen Inc. to apply Morphotek's proprietary MORPHODOMA® technology to Amgen's proprietary cell lines to generate high-titer antibody producing cell lines for scaleable manufacturing.
 

Black Duck Software, Inc.

Black Duck Software Secures $12M in Series B Financing Led by Fidelity Ventures

Black Duck Software Secures $12M in Series B Financing Led by Fidelity Ventures

June 6, 2005

With Participation from Intel, SAP Ventures, and Original Investors Flagship Ventures, General Catalyst Partners, and Red Hat

IntelliVid

IntelliVid Announces Funding

IntelliVid Announces Funding

June 7, 2005

Company Offers Groundbreaking Intelligent Video Analysis Solutions for Retail Loss Prevention

Brainshark, Inc.

Brainshark, Inc. Secures $6.9 Million Financing in Oversubscribed Round

Brainshark, Inc. Secures $6.9 Million Financing in Oversubscribed Round

June 13, 2005

Bullish Outlook For Company's Leadership in Rapidly Growing Segment of Web-based Communications Market Attracts Investment from New and Existing Investors to Fund Expansion

Adnexus Therapeutics

Compound Therapeutics Appoints Dr. John Mendlein as CEO

Compound Therapeutics Appoints Dr. John Mendlein as CEO

June 15, 2005

Biotech executive to accelerate partnering and development of a breakthrough class of pharmaceuticals

Selventa

Genstruct Expands Scientific Advisory Board and Management Team with Industry Experts

Genstruct Expands Scientific Advisory Board and Management Team with Industry Experts

June 20, 2005

CAMBRIDGE, Mass., June 20 /PRNewswire/ -- Genstruct, Inc., a knowledge-driven discovery company using systems biology to discover biomarkers that increase the effectiveness of drug discovery and development, today announced that Alan Williamson, Ph.D. has joined its Scientific Advisory Board (SAB). The company has also appointed Charlie Lieu as director of Business Development and Marketing.

IntelliVid

IntelliVid Announces New Board Member, Board of Advisors

IntelliVid Announces New Board Member, Board of Advisors

June 21, 2005

Intelligent Video Analysis Leader Names Industry Visionary to Board of Directors and Unveils Advisory Board of Industry Leaders

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 21, 2005--IntelliVid Corporation, the leader in Intelligent Video Analysis solutions for retail loss prevention, today named Domenic J. LaCava to its Board of Directors and unveiled its Advisory Board of senior industry executives.

Adnexus Therapeutics

Compound Therapeutics Announces Initiation of IND-Enabling Safety Studies with Lead Oncology Product

Compound Therapeutics Announces Initiation of IND-Enabling Safety Studies with Lead Oncology Product

June 22, 2005

First of a New Class of Protein Therapeutics

Waltham, MA, June 22, 2005 -- Compound Therapeutics announced that it has initiated IND-enabling animal safety studies with CT-322, its lead product. CT-322 is an AdNectin blocker of vascular endothelial growth factor receptor-2 (VEGFR-2), a receptor that is the key driver of angiogenesis. Inhibition of this biological pathway has been demonstrated to be highly effective in treating many cancers, as well as in treating age-related macular degeneration (AMD).

Zalicus

CombinatoRx Licenses CRx-026 Territory Right to HenKan

CombinatoRx Licenses CRx-026 Territory Right to HenKan

July 18, 2005

Partnership Accelerates Development and Commercialization of CRx-026 in Taiwan, China and South Korea

BOSTON, MA and TAIPEI, TAIWAN -- July 18, 2005 - CombinatoRx, Incorporated, a privately held biopharmaceutical company, and HenKan Pharmaceutical Company today announced the signing of a territorial license agreement for CRx-026, a novel dual action anti-cancer agent in clinical development for solid tumors.